• Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M et al. (2009). The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18: 40814088.
  • Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J et al. (2010). Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95: 50285036.
  • De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, Umbdenstock T et al. (2012). Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Brit J Pharmacol 168: 339353.
  • Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU et al. (2010). New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105116.
  • Ferre T, Riu E, Franckhauser S, Agudo J, Bosch F (2003). Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 46: 16621668.
  • Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW et al. (2003). Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370373.
  • International Diabetes Federation (2011). IDF Diabetes Atlas, International Diabetes Federation (Ed), 5th Edn. International Diabetes Federation: Brussels.
  • Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikainen LP et al. (2012). Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 44: 269276.
  • Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H et al. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 25602566.
  • Nissim I, Horyn O, Daikhin Y, Wehrli SL, Yudkoff M, Matschinsky FM (2012). Effects of a glucokinase activator on hepatic intermediary metabolism: study with (13)C-isotopomer-based metabolomics. Biochem J 444: 537551.
  • O'Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB (1999). Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 20222027.
  • Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S et al. (2009). Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30: 15121526.
  • Rees MG, Wincovitch S, Schultz J, Waterstradt R, Beer NL, Baltrusch S et al. (2012). Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55: 114122.
  • Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H et al. (2007). Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 13311336.
  • Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD et al. (2011). Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7: e1001324.
  • Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B et al. (2011). Human metabolic individuality in biomedical and pharmaceutical research. Nature 477: 5460.